SpringWorks Therapeutics announced the presentation of additional data from the Phase 3 DeFi trial at the 2023 Connective Tissue Oncology Society Annual Meeting, being held November 1-4, 2023. These data demonstrate the impact of nirogacestat, an investigational gamma secretase inhibitor, on physical and role functioning in adults with desmoid tumors. Data from the DeFi trial demonstrated statistically significant and clinically meaningful improvements across all primary and key secondary endpoints and were previously presented at leading medical congresses and published in the March 9, 2023 edition of the New England Journal of Medicine.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
- SpringWorks Therapeutics to participate in a conference call with JPMorgan
- SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
- SpringWorks Therapeutics names Dr. Tai-An Lin as Chief Scientific Officer